Related Experiment Videos
Cancer immunotherapy targeting WT1 protein
1Department of Clinical Laboratory Science, Osaka University Medical School, Suita City, Japan. sugiyama@sahs.med.osaka-u.ac.jp
International Journal of Hematology
|September 7, 2002
Summary
The Wilms tumor gene (WT1) protein is overexpressed in many cancers, acting as a promising tumor antigen. WT1-specific T-cells and antibodies confirm its immunogenicity, supporting its use in cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The Wilms tumor gene (WT1) is implicated in various malignancies, including leukemias and solid tumors like lung and breast cancer.
- WT1 protein functions oncogenically and is recognized as a potential tumor antigen.
- WT1 protein has demonstrated potential as a tumor rejection antigen in preclinical models.
Purpose of the Study:
- To investigate the immunogenicity of WT1 protein in cancer patients.
- To evaluate the potential of WT1 as a target for cancer immunotherapy.
Main Methods:
- Stimulation of peripheral blood mononuclear cells with WT1 peptides restricted by HLA-A*2402 and HLA-A*0201.
- Detection of WT1-specific cytotoxic T-lymphocytes (CTLs).
- Assay for WT1-specific immunoglobulin M (IgM) and IgG antibodies in patient sera.
Main Results:
- WT1 peptides successfully elicited WT1-specific CTLs in vitro.
- These CTLs demonstrated the ability to kill leukemia and solid tumor cells expressing WT1.
- WT1-specific IgM and IgG antibodies were detected in patients with hematopoietic malignancies.
Conclusions:
- WT1 protein is immunogenic in cancer patients, evidenced by T-cell and antibody responses.
- WT1 represents a promising tumor antigen for developing novel cancer immunotherapies.
- Targeting WT1 holds potential for treating leukemias and solid tumors, including lung and breast cancer.